Chong Kun Dang Pharmaceutical Corp.
KRX:185750.KS
114600 (KRW) • At close October 17, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) KRW.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,669,404.439 | 1,488,344.729 | 1,343,559.363 | 1,303,005.524 | 1,079,337.662 | 956,218.889 | 884,362.808 | 831,985.53 | 592,493.474 | 544,129.759 | 86,318.152 |
| Cost of Revenue
| 1,014,059.891 | 945,705.337 | 847,741.079 | 813,865.705 | 675,059.109 | 575,815.577 | 524,706.462 | 497,098.889 | 296,312.149 | 263,788.537 | 40,086.525 |
| Gross Profit
| 655,344.548 | 542,639.392 | 495,818.284 | 489,139.819 | 404,278.553 | 380,403.312 | 359,656.346 | 334,886.641 | 296,181.325 | 280,341.222 | 46,231.627 |
| Gross Profit Ratio
| 0.393 | 0.365 | 0.369 | 0.375 | 0.375 | 0.398 | 0.407 | 0.403 | 0.5 | 0.515 | 0.536 |
| Reseach & Development Expenses
| 140,234.542 | 176,324.876 | 163,276.712 | 146,663.978 | 98,623.649 | 77,034.472 | 65,051.785 | 67,181.698 | 57,754.938 | 42,868.918 | 11,176.693 |
| General & Administrative Expenses
| 24,993.025 | 22,563.488 | 20,235.339 | 17,880.273 | 21,899.401 | 30,425.722 | 26,324.476 | 28,876.741 | 28,068.34 | 22,955.932 | 4,989.75 |
| Selling & Marketing Expenses
| 106,382.803 | 93,887.57 | 82,478.568 | 73,489.077 | 76,829.812 | 86,732.29 | 77,455.534 | 72,435.624 | 66,510.105 | 66,795.647 | 8,776.439 |
| SG&A
| 256,728.625 | 116,451.058 | 102,713.907 | 91,369.35 | 98,729.213 | 117,158.012 | 103,780.01 | 101,312.365 | 94,578.445 | 89,751.579 | 13,766.189 |
| Other Expenses
| -11,694.443 | 139,957.397 | 135,068.971 | 127,170.612 | 132,350.079 | -3,984.227 | 811.804 | 2,302.247 | -21,793.178 | -687.662 | -382.59 |
| Operating Expenses
| 408,657.61 | 432,733.331 | 401,059.59 | 365,203.94 | 329,702.941 | 304,663.418 | 281,891.353 | 273,637.097 | 253,476.239 | 226,410.998 | 38,692.654 |
| Operating Income
| 246,686.938 | 109,906.062 | 94,758.694 | 123,935.879 | 74,575.613 | 75,739.894 | 77,764.992 | 61,249.545 | 42,705.086 | 53,930.224 | 7,538.973 |
| Operating Income Ratio
| 0.148 | 0.074 | 0.071 | 0.095 | 0.069 | 0.079 | 0.088 | 0.074 | 0.072 | 0.099 | 0.087 |
| Total Other Income Expenses Net
| -5,283.92 | -12,740.995 | -14,164.84 | -2,096.922 | -2,754.436 | -7,399.547 | -3,165.832 | -4,461.832 | -27,567.439 | -5,448.078 | -1,531.563 |
| Income Before Tax
| 241,403.018 | 97,165.067 | 80,593.854 | 121,838.957 | 71,821.177 | 68,340.348 | 74,599.161 | 56,787.712 | 15,137.647 | 48,482.146 | 6,007.41 |
| Income Before Tax Ratio
| 0.145 | 0.065 | 0.06 | 0.094 | 0.067 | 0.071 | 0.084 | 0.068 | 0.026 | 0.089 | 0.07 |
| Income Tax Expense
| 27,995.661 | 17,187.287 | 38,237.382 | 31,434.068 | 18,845.892 | 26,635.943 | 20,870.907 | 15,841.608 | 21,910.388 | 13,328.405 | 1,590.436 |
| Net Income
| 212,521.171 | 80,953.361 | 42,720.381 | 91,632.759 | 53,881.646 | 42,398.535 | 53,807.202 | 40,946.103 | -6,772.741 | 35,153.741 | 4,416.974 |
| Net Income Ratio
| 0.127 | 0.054 | 0.032 | 0.07 | 0.05 | 0.044 | 0.061 | 0.049 | -0.011 | 0.065 | 0.051 |
| EPS
| 16,704 | 6,608.77 | 3,434.22 | 7,317.59 | 4,300.43 | 3,382.95 | 4,066.13 | 3,249.02 | -537.28 | 2,789.35 | 350.72 |
| EPS Diluted
| 16,704 | 6,608.77 | 3,434.22 | 7,317.59 | 4,300.43 | 3,382.95 | 4,066.13 | 3,249.02 | -537.28 | 2,789.35 | 350.72 |
| EBITDA
| 283,629.155 | 144,825.32 | 112,946.014 | 150,438.368 | 100,522.427 | 93,776.867 | 99,819.503 | 87,714.999 | 44,453.835 | 74,317.54 | 10,223.911 |
| EBITDA Ratio
| 0.17 | 0.097 | 0.084 | 0.115 | 0.093 | 0.098 | 0.113 | 0.105 | 0.075 | 0.137 | 0.118 |